Kyntra Bio (NASDAQ:KYNB) Releases Quarterly Earnings Results, Misses Expectations By $0.38 EPS

Kyntra Bio (NASDAQ:KYNB) released its quarterly earnings results on Monday. The company reported ($3.74) EPS for the quarter, missing the consensus estimate of ($3.36) by ($0.38), Zacks reports.

Kyntra Bio Price Performance

NASDAQ KYNB traded down $0.15 during mid-day trading on Monday, reaching $6.80. 15,619 shares of the stock were exchanged, compared to its average volume of 26,389. Kyntra Bio has a 1-year low of $4.85 and a 1-year high of $12.60. The firm’s fifty day simple moving average is $7.04. The firm has a market capitalization of $27.54 million, a PE ratio of 0.15 and a beta of 1.03.

Analysts Set New Price Targets

Several research firms have recently commented on KYNB. Wall Street Zen upgraded shares of Kyntra Bio from a “sell” rating to a “hold” rating in a research report on Saturday, April 18th. HC Wainwright upgraded shares of Kyntra Bio to a “strong-buy” rating in a research report on Friday, February 27th. Weiss Ratings began coverage on shares of Kyntra Bio in a research report on Wednesday, January 14th. They issued a “sell (d+)” rating on the stock. Finally, Zacks Research lowered shares of Kyntra Bio from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold”.

Kyntra Bio Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.